Navigation Links
Genomic Health to Present at the JMP Securities Healthcare Conference
Date:9/21/2011

REDWOOD CITY, Calif., Sept. 21, 2011 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Dean Schorno, Genomic Health's Chief Financial Officer, will present at the JMP Securities Healthcare Conference in New York City on Tuesday, September 27, 2011 at 3:00 p.m. Eastern Time (ET).  

To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com.  Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads.  An archived replay will be available for three months beginning 24 hours after the live presentation.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.  Its lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer.  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease.  As of June 30, 2011, more than 10,000 physicians in over 60 countries had ordered more than 200,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional stages of breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline, the ability of the company to develop additional tests in the future, and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests;  the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly  Report  on Form 10-Q  for the period ended June 30, 2011. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... LONDON , May 30, 2016 ... to eliminate viral hepatitis by 2030. At the 69 th ... first ever Global Viral Hepatitis Strategy, signalling the greatest global ... sets a goal of eliminating hepatitis B and C by ... which, if reached, will reduce annual deaths by 65% and ...
(Date:5/30/2016)... DUBAI , May 30, 2016 ... parents of premature babies to seek an eye examination ... avoid blinding condition     Moorfields Eye ... Hospital in London , has identified premature babies ... vision problems, because of their particular vulnerability to retinopathy of prematurity ...
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... Splashtop Inc., the worldwide leader in high performance cross-screen access, ... leading provider of secure mobile remote access solution for Japan enterprises. , ... solution. Splashtop for CACHATTO will be available as an integrated add-on secure ...
(Date:5/31/2016)... ... , ... DDL, Inc. announced today it has expanded the scope of its ... 594-1 and ISO 594-2 testing for conical (Luer) fittings. , A conical Luer ... devices (e.g. a syringe and hypodermic needle) that carry small volumes of fluids. There ...
(Date:5/31/2016)... ... 2016 , ... Like jewels in a crown, the multiple awards presented to ... to Ontario’s leading day spa and one of Canada’s few accredited 5 Star Spas! ... concept to combine spa services with hair and beauty services and has ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education ... , David G. Lewallen, MD, began his term as president in March, succeeding ... Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, ...
(Date:5/31/2016)... Aviv (PRWEB) , ... May 31, 2016 , ... ... the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 ... and publishes a series of research reports evaluating these innovative vendors and their ...
Breaking Medicine News(10 mins):